tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CMPS Stock Latest News

Positive Clinical Results and Strategic Advancements Drive Buy Rating for COMPASS Pathways
RatingsPositive Clinical Results and Strategic Advancements Drive Buy Rating for COMPASS Pathways
2d ago
CMPS
Psychedelic: Bright Minds reports preclinical BMB-201 results
PremiumThe Fly
Psychedelic: Bright Minds reports preclinical BMB-201 results
10d ago
CMPS
CYBN
Compass Pathways’ COMP360 psilocybin shows positive efficacy, tolerance results
PremiumThe Fly
Compass Pathways’ COMP360 psilocybin shows positive efficacy, tolerance results
13d ago
CMPS
Psychedelic: Exclusive talk with biopharma company Reunion Neuroscience
PremiumThe Fly
Psychedelic: Exclusive talk with biopharma company Reunion Neuroscience
17d ago
ATAI
CMND
Compass Pathways’ Phase III Study on COMP360: A Potential Game-Changer for Depression Treatment
PremiumCompany Announcements
Compass Pathways’ Phase III Study on COMP360: A Potential Game-Changer for Depression Treatment
23d ago
CMPS
Compass Pathways’ Phase III Study on COMP360: A Potential Game-Changer for Treatment-resistant Depression
PremiumCompany AnnouncementsCompass Pathways’ Phase III Study on COMP360: A Potential Game-Changer for Treatment-resistant Depression
25d ago
CMPS
Optimistic Buy Rating for COMPASS Pathways Amidst Promising Phase 3 Trials and Regulatory Support
Premium
Ratings
Optimistic Buy Rating for COMPASS Pathways Amidst Promising Phase 3 Trials and Regulatory Support
1M ago
CMPS
Cathie Wood ‘Buys the Dip’ in Block Stock; Sells Shopify Shares
Premium
Market News
Cathie Wood ‘Buys the Dip’ in Block Stock; Sells Shopify Shares
1M ago
GH
XYZ
Psychedelic: Cybin receives European approval for EMBRACE study
PremiumThe Fly
Psychedelic: Cybin receives European approval for EMBRACE study
1M ago
CMND
CMPS
Compass Pathways’ Phase III Study on COMP360: A New Hope for Treatment-resistant Depression
PremiumCompany Announcements
Compass Pathways’ Phase III Study on COMP360: A New Hope for Treatment-resistant Depression
1M ago
CMPS
COMPASS Pathways: Leading the Psychedelic Medicine Revolution with Promising Psilocybin Trials and Strong Industry Positioning
PremiumRatings
COMPASS Pathways: Leading the Psychedelic Medicine Revolution with Promising Psilocybin Trials and Strong Industry Positioning
1M ago
CMPS
Compass Pathways’ COMP360 Study: A New Hope for Treatment-resistant Depression?
PremiumCompany Announcements
Compass Pathways’ COMP360 Study: A New Hope for Treatment-resistant Depression?
1M ago
CMPS
Compass Pathways price target lowered to $40 from $45 at H.C. Wainwright
PremiumThe FlyCompass Pathways price target lowered to $40 from $45 at H.C. Wainwright
1M ago
CMPS
Compass Pathways’ Phase III Study on COMP360: A Potential Breakthrough in Treating Depression
Premium
Company Announcements
Compass Pathways’ Phase III Study on COMP360: A Potential Breakthrough in Treating Depression
1M ago
CMPS
Compass Pathways Reports Strong Progress in Q2 2025
Premium
Company Announcements
Compass Pathways Reports Strong Progress in Q2 2025
1M ago
CMPS
Compass Pathways’ Earnings Call Highlights Success and Challenges
PremiumCompany Announcements
Compass Pathways’ Earnings Call Highlights Success and Challenges
2M ago
CMPS
Positive Buy Rating for COMPASS Pathways Driven by Strategic Progress and Financial Stability
PremiumRatings
Positive Buy Rating for COMPASS Pathways Driven by Strategic Progress and Financial Stability
2M ago
CMPS
Compass Pathways’ Phase III Study on COMP360: A Potential Game-Changer in Depression Treatment
PremiumCompany Announcements
Compass Pathways’ Phase III Study on COMP360: A Potential Game-Changer in Depression Treatment
2M ago
CMPS
Psychedelic: Filament reports compassionate use approval for psilocybin
PremiumThe Fly
Psychedelic: Filament reports compassionate use approval for psilocybin
2M ago
PBM
ATAI
Compass Pathways reports Q2 EPS (41c) vs. (56c) last year
PremiumThe FlyCompass Pathways reports Q2 EPS (41c) vs. (56c) last year
2M ago
CMPS
Compass Pathways’ Psilocybin Study: A Potential Game-Changer for Depression Treatment
Premium
Company Announcements
Compass Pathways’ Psilocybin Study: A Potential Game-Changer for Depression Treatment
2M ago
CMPS
Compass Pathways Appoints Justin Gover to Board
Premium
Company Announcements
Compass Pathways Appoints Justin Gover to Board
2M ago
8K
CMPS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >